These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 18794549)
1. Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. Jakacki RI; Hamilton M; Gilbertson RJ; Blaney SM; Tersak J; Krailo MD; Ingle AM; Voss SD; Dancey JE; Adamson PC J Clin Oncol; 2008 Oct; 26(30):4921-7. PubMed ID: 18794549 [TBL] [Abstract][Full Text] [Related]
2. Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Prados MD; Lamborn KR; Chang S; Burton E; Butowski N; Malec M; Kapadia A; Rabbitt J; Page MS; Fedoroff A; Xie D; Kelley SK Neuro Oncol; 2006 Jan; 8(1):67-78. PubMed ID: 16443950 [TBL] [Abstract][Full Text] [Related]
3. A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a Children's Oncology Group phase 1 consortium study. Hummel TR; Wagner L; Ahern C; Fouladi M; Reid JM; McGovern RM; Ames MM; Gilbertson RJ; Horton T; Ingle AM; Weigel B; Blaney SM Pediatr Blood Cancer; 2013 Sep; 60(9):1452-7. PubMed ID: 23554030 [TBL] [Abstract][Full Text] [Related]
4. Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411). Schafer ES; Rau RE; Berg SL; Liu X; Minard CG; Bishop AJR; Romero JC; Hicks MJ; Nelson MD; Voss S; Reid JM; Fox E; Weigel BJ; Blaney SM Pediatr Blood Cancer; 2020 Feb; 67(2):e28073. PubMed ID: 31724813 [TBL] [Abstract][Full Text] [Related]
5. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study. Wagner LM; Perentesis JP; Reid JM; Ames MM; Safgren SL; Nelson MD; Ingle AM; Blaney SM; Adamson PC Pediatr Blood Cancer; 2010 Apr; 54(4):538-45. PubMed ID: 20049936 [TBL] [Abstract][Full Text] [Related]
6. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study. Bagatell R; Norris R; Ingle AM; Ahern C; Voss S; Fox E; Little AR; Weigel BJ; Adamson PC; Blaney S Pediatr Blood Cancer; 2014 May; 61(5):833-9. PubMed ID: 24249672 [TBL] [Abstract][Full Text] [Related]
7. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial. DuBois SG; Marachelian A; Fox E; Kudgus RA; Reid JM; Groshen S; Malvar J; Bagatell R; Wagner L; Maris JM; Hawkins R; Courtier J; Lai H; Goodarzian F; Shimada H; Czarnecki S; Tsao-Wei D; Matthay KK; Mosse YP J Clin Oncol; 2016 Apr; 34(12):1368-75. PubMed ID: 26884555 [TBL] [Abstract][Full Text] [Related]
8. Phase I trial of lapatinib in children with refractory CNS malignancies: a Pediatric Brain Tumor Consortium study. Fouladi M; Stewart CF; Blaney SM; Onar-Thomas A; Schaiquevich P; Packer RJ; Gajjar A; Kun LE; Boyett JM; Gilbertson RJ J Clin Oncol; 2010 Sep; 28(27):4221-7. PubMed ID: 20713864 [TBL] [Abstract][Full Text] [Related]
9. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Wagner LM; Crews KR; Iacono LC; Houghton PJ; Fuller CE; McCarville MB; Goldsby RE; Albritton K; Stewart CF; Santana VM Clin Cancer Res; 2004 Feb; 10(3):840-8. PubMed ID: 14871959 [TBL] [Abstract][Full Text] [Related]
10. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. van den Bent MJ; Brandes AA; Rampling R; Kouwenhoven MC; Kros JM; Carpentier AF; Clement PM; Frenay M; Campone M; Baurain JF; Armand JP; Taphoorn MJ; Tosoni A; Kletzl H; Klughammer B; Lacombe D; Gorlia T J Clin Oncol; 2009 Mar; 27(8):1268-74. PubMed ID: 19204207 [TBL] [Abstract][Full Text] [Related]
11. Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. Prados MD; Yung WK; Wen PY; Junck L; Cloughesy T; Fink K; Chang S; Robins HI; Dancey J; Kuhn J Cancer Chemother Pharmacol; 2008 May; 61(6):1059-67. PubMed ID: 17694310 [TBL] [Abstract][Full Text] [Related]
12. Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. Wagner LM; Villablanca JG; Stewart CF; Crews KR; Groshen S; Reynolds CP; Park JR; Maris JM; Hawkins RA; Daldrup-Link HE; Jackson HA; Matthay KK J Clin Oncol; 2009 Mar; 27(8):1290-6. PubMed ID: 19171709 [TBL] [Abstract][Full Text] [Related]
13. Phase I study of temozolomide combined with oral etoposide in children with malignant glial tumors. Ruggiero A; Rizzo D; Attinà G; Lazzareschi I; Maurizi P; Ridola V; Mastrangelo S; Migliorati R; Bertolini P; Colosimo C; Riccardi R J Neurooncol; 2013 Jul; 113(3):513-8. PubMed ID: 23666235 [TBL] [Abstract][Full Text] [Related]
14. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma. Korones DN; Benita-Weiss M; Coyle TE; Mechtler L; Bushunow P; Evans B; Reardon DA; Quinn JA; Friedman H Cancer; 2003 Apr; 97(8):1963-8. PubMed ID: 12673724 [TBL] [Abstract][Full Text] [Related]
15. Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Reardon DA; Nabors LB; Mason WP; Perry JR; Shapiro W; Kavan P; Mathieu D; Phuphanich S; Cseh A; Fu Y; Cong J; Wind S; Eisenstat DD; Neuro Oncol; 2015 Mar; 17(3):430-9. PubMed ID: 25140039 [TBL] [Abstract][Full Text] [Related]
16. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial. Mody R; Naranjo A; Van Ryn C; Yu AL; London WB; Shulkin BL; Parisi MT; Servaes SE; Diccianni MB; Sondel PM; Bender JG; Maris JM; Park JR; Bagatell R Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783 [TBL] [Abstract][Full Text] [Related]
17. A Phase 1 Trial of TPI 287 as a Single Agent and in Combination With Temozolomide in Patients with Refractory or Recurrent Neuroblastoma or Medulloblastoma. Mitchell D; Bergendahl G; Ferguson W; Roberts W; Higgins T; Ashikaga T; DeSarno M; Kaplan J; Kraveka J; Eslin D; Werff AV; Hanna GK; Sholler GL Pediatr Blood Cancer; 2016 Jan; 63(1):39-46. PubMed ID: 26235333 [TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma. Broniscer A; Baker SJ; Stewart CF; Merchant TE; Laningham FH; Schaiquevich P; Kocak M; Morris EB; Endersby R; Ellison DW; Gajjar A Clin Cancer Res; 2009 Jan; 15(2):701-7. PubMed ID: 19147777 [TBL] [Abstract][Full Text] [Related]
20. Phase I trial of single-dose temozolomide and continuous administration of o6-benzylguanine in children with brain tumors: a pediatric brain tumor consortium report. Broniscer A; Gururangan S; MacDonald TJ; Goldman S; Packer RJ; Stewart CF; Wallace D; Danks MK; Friedman HS; Poussaint TY; Kun LE; Boyett JM; Gajjar A Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6712-8. PubMed ID: 18006772 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]